Arax Advisory Partners
JBIO icon

Arax Advisory Partners’s Jade Biosciences JBIO Stock Holding History

Arax Advisory Partners’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.55K Buy
385
+281
+270% +$5.86K ﹤0.01% 4403
2026
Q1 		$1.46K Buy
104
+101
+3,367% +$1.46K ﹤0.01% 3196
2025
Q4 		$47 Sell
3
-152
-98% -$1.78K ﹤0.01% 3924
2025
Q3 		$1.34K Buy
155
+152
+5,067% +$1.24K ﹤0.01% 3195
2025
Q2 		$30 Hold
3
– – ﹤0.01% 3010
2025
Q1 		$294 Hold
3
– – ﹤0.01% 2579
2024
Q4 		$311 Hold
3
– – ﹤0.01% 2368
2024
Q3 		$245 Hold
3
– – ﹤0.01% 2496
2024
Q2 		$195 Buy
+3
New +$1.99K ﹤0.01% 2442

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Arax Advisory Partners's JBIO Position: Q2 2026 in Review

Arax Advisory Partners increased its Jade Biosciences (JBIO) stake by 270% in Q2 2026, buying an estimated $5.86K and bringing the position to 385 shares worth $8.55K. The position accounts for ﹤0.01% of the portfolio, ranked #4403.

Arax Advisory Partners first reported a position in JBIO in Q2 2024 and has held it in 9 quarters since. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Arax Advisory Partners held 385 shares of Jade Biosciences worth $8.55K as of Q2 2026.
  • Arax Advisory Partners bought 281 Jade Biosciences shares in Q2 2026, an estimated $5.86K.
  • Jade Biosciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4403 holding.
  • Arax Advisory Partners first reported a position in Jade Biosciences in Q2 2024 and has held it in 9 quarters since.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.